These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27672004)

  • 1. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
    Allegra S; De Francia S; Cusato J; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2016 Nov; 68(11):1417-1421. PubMed ID: 27672004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
    Allegra S; Cusato J; De Francia S; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2017 May; 69(5):525-528. PubMed ID: 27230486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
    Lu MY; Wang N; Wu WH; Lai CW; Kuo PH; Chiang PH; Lin KH; Wu TH
    Clin Ther; 2015 Aug; 37(8):1751-60. PubMed ID: 26093827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
    Allegra S; De Francia S; Longo F; Massano D; Cusato J; Arduino A; Pirro E; Piga A; D'Avolio A
    Biomed Pharmacother; 2016 Dec; 84():1510-1512. PubMed ID: 27881236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
    Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
    Maker GL; Siva B; Batty KT; Trengove RD; Ferrari P; Olynyk JK
    Nephrology (Carlton); 2013 Mar; 18(3):188-93. PubMed ID: 23332024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major.
    Lu MY; Lin TH; Chiang PH; Kuo PH; Wang N; Wu WH; Lin KH; Wu TH
    Ther Drug Monit; 2017 Apr; 39(2):185-191. PubMed ID: 28141745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.
    Chauzit E; Bouchet S; Micheau M; Mahon FX; Moore N; Titier K; Molimard M
    Ther Drug Monit; 2010 Aug; 32(4):476-81. PubMed ID: 20386360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
    Mattioli F; Puntoni M; Marini V; Fucile C; Milano G; Robbiano L; Perrotta S; Pinto V; Martelli A; Forni GL
    Eur J Haematol; 2015 Apr; 94(4):310-7. PubMed ID: 25081908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
    Daar S; Pathare A; Nick H; Kriemler-Krahn U; Hmissi A; Habr D; Taher A
    Eur J Haematol; 2009 Jun; 82(6):454-7. PubMed ID: 19191863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
    Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
    Miyazawa K; Ohyashiki K; Urabe A; Hata T; Nakao S; Ozawa K; Ishikawa T; Kato J; Tatsumi Y; Mori H; Kondo M; Taniguchi J; Tanii H; Rojkjaer L; Omine M
    Int J Hematol; 2008 Jul; 88(1):73-81. PubMed ID: 18597054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
    Piga A; Fracchia S; Lai ME; Cappellini MD; Hirschberg R; Habr D; Wegener A; Bouillaud E; Forni GL
    Br J Haematol; 2015 Mar; 168(6):882-90. PubMed ID: 25402221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial.
    Lai YR; Liu RR; Li CF; Huang SL; Li Q; Habr D; Martin N; Shen ZX
    Transfus Med; 2013 Dec; 23(6):389-96. PubMed ID: 24147622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.